Background and Context:
In Canada, the oncology community believed that the Common Drug Review (CDR) required a new approach to address the needs of Canadian cancer patients, resulting in the implementation of the pan-Canadian Oncology Drug Review. (pCODR)
pCODR was established with input from a number of patient-centered cancer organisations across Canada working alongside cancer agencies, provincial governments and Provincial Deputy Ministers of Health, with the exception of Quebec. Since implementation of pCODR, Canada has seen unprecedented opportunities for cancer patient input and engagement in the Canadian patient community in the HTA decision-making process.
Referencing international HTA best practices and drawing on lessons learned, the Canadian Cancer Action Network will deliver (from the perspective of the patient community) a comprehensive overview to our international colleagues of how cancer patients and advocacy groups inform patient outcomes in Canada. This will include how the Canadian HTA system solicits and integrates patient input into decision-making in a collaborative, open and transparent process.
CCAN will highlight the impact and value of various tools and resources designed to assist Canadian patient advocacy groups in patient submissions, centering on the development and implementation of a patient advocacy guide, a first for Canada, created in collaboration with pCODR and the Li Ka Shing Knowledge Institute, St. Michael’s Hospital. (Toronto, Canada)
CCAN will summarize current Canadian initiatives introducing support services to patient advocacy groups, drawing on a patient engagement model implemented by the National Institute for Health and Clinical Excellence, and how we anticipate this will significantly change the future for patient advocacy submissions in Canada.
Outcomes/What was learned:
With the guide in practice (and with a Patient HTS Navigator working to support the patient advocacy community) CCAN will summarize the key strengths in terms of application, value and overall impact to improved HTA in Canada.